Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Jagdeep Nanchahal, Professor of Hand, Plastic and Reconstructive Surgery at the Kennedy Institute, and his team have won the International Dupuytren Award for a trial repurposing anti-TNF in Dupuytren’s disease.

Horizontal portrait of Jagdeep Nanchahal

Dupuytren's disease affects about 4% of the UK population. It causes fingers to irreversibly curl into the palm, which can be extremely disabling. There is no approved treatment for early disease and patients with established deformities often require surgery to cut or remove the diseased tissue to straighten the fingers.

The winning paper "Anti-Tumour Necrosis Factor Therapy for Dupuytren's Disease: A Randomised Dose Response Proof of Concept Phase 2a Clinical Trial" explained how Professor Nanchahal's team identified tumour necrosis factor (TNF) as a potential therapeutic target and showed in this trial that injecting a concentrated formulation of anti-TNF directly into the diseased tissue effectively inhibits the cells causing the disease. The team have now completed recruitment to their phase 2b trial in patients with early stage disease to assess if injecting nodules of early stage Dupuytren's disease with a TNF inhibitor prevents disease progression. If successful, patients could receive a simple injection that would preserve hand function and avoid the need for subsequent more invasive treatments.

Professor Nanchahal said, "It is a great honour to receive this award on behalf of my team, and a recognition of our efforts to find a treatment for this debilitating disease."

The International Dupuytren Award, presented annually by the International Dupuytren Society, recognises exceptional scientific publications on research or clinical treatment of Dupuytren and/or Ledderhose disease.

Similar stories

£1.2M to improve diagnosis of emergency spinal condition

The National Institute for Health and Care Research has awarded an Advanced Fellowship to Dr David Metcalfe to study the diagnosis of the spinal condition, cauda equina syndrome.

Professor Chris Lavy appointed to WHO technical advisory group

Congratulations to Professor Chris Lavy, who has been appointed to the World Health Organization’s (WHO) technical advisory group for integrated clinical care for a period of two years.

Oxford receives NIHR funding to test anti-TNF on post operative delirium

Researchers at the University of Oxford have been awarded a grant from the National Institute for Health and Care Research (NIHR) to investigate whether anti-tumour necrosis factor (TNF) therapy can reduce or prevent post operative delirium/cognitive deficit.

Gene variant links trigger finger and carpal tunnel syndrome

A new NDORMS study, published in The Lancet Rheumatology, has found a genetic variant that increases the risk of both carpal tunnel syndrome and trigger finger, and opens the door for new therapies that involve blocking the IGF-1 pathway.

Kennedy programmes support early career researchers

Since 2013 the Kennedy Institute of Rheumatology has been running a Career Development Programme, a scheme to help early career researchers launch their own independent laboratories, and more recently the Innovator Investigator Programme to bring new technologies to core research themes.

OCTRU collaboration boosts understanding of COVID vaccine response

Working with researchers across multiple universities, the Oxford Clinical Trials Unit (OCTRU) played a key role in delivering results of the national VROOM trial (Vaccine Response On Off Methotrexate).